WEKO3
アイテム
{"_buckets": {"deposit": "e155faf3-71f3-42e6-8496-5edb178ada08"}, "_deposit": {"created_by": 2, "id": "15296", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "15296"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00015296", "sets": ["30"]}, "author_link": ["56517", "56514", "56516", "56522", "56515", "56521", "56523", "56524", "56526", "56525", "56513", "56520", "56519", "56518"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "338", "bibliographicPageStart": "331", "bibliographicVolumeNumber": "67", "bibliographic_titles": [{"bibliographic_title": "Cancer chemotherapy and pharmacology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status \u003c/=3, age \u003c/=80 years, and stage IIIB-IV disease. In addition, EGFR mutations were analyzed in 24 patients. RESULTS: Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS. CONCLUSIONS: The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib.", "subitem_description_type": "Abstract"}]}, "item_2_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "The original publication is available at www.springerlink.com", "subitem_description_type": "Other"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Cancer Chemotherapy and Pharmacology, 67(2), pp.331-338; 2011", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer Berlin"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "20401612", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s00280-010-1325-x", "subitem_relation_type_select": "DOI"}}]}, "item_2_relation_42": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "http://hdl.handle.net/10069/26688"}]}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© Springer-Verlag 2010"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00598397", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03445704", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14320843", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yamaguchi, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "56513", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Soda, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "56514", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Yoichi"}], "nameIdentifiers": [{"nameIdentifier": "56515", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takasu, Mineyo"}], "nameIdentifiers": [{"nameIdentifier": "56516", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomonaga, Nanae"}], "nameIdentifiers": [{"nameIdentifier": "56517", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakano, Hirofumi"}], "nameIdentifiers": [{"nameIdentifier": "56518", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Doi, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "56519", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakatomi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "56520", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagashima, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "56521", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takatani, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "56522", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "56523", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayashi, Tomayoshi"}], "nameIdentifiers": [{"nameIdentifier": "56524", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukamoto, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "56525", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "56526", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-23"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CCP67_331.pdf", "filesize": [{"value": "127.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 127300.0, "url": {"label": "CCP67_331.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/15296/files/CCP67_331.pdf"}, "version_id": "4c7e72d3-7592-4971-b1b1-f6c392d56c72"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Gefitinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-small cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SP-A", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SP-D", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer."}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/23169", "pubdate": {"attribute_name": "公開日", "attribute_value": "2010-05-26"}, "publish_date": "2010-05-26", "publish_status": "0", "recid": "15296", "relation": {}, "relation_version_is_last": true, "title": ["Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer."], "weko_shared_id": 2}
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
http://hdl.handle.net/10069/23169
http://hdl.handle.net/10069/2316901fe6bdf-82d4-46c2-ab55-01306e72de0e
名前 / ファイル | ライセンス | アクション |
---|---|---|
CCP67_331.pdf (127.3 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2010-05-26 | |||||
タイトル | ||||||
タイトル | Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Gefitinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Non-small cell lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | SP-A | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | SP-D | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Yamaguchi, Hiroyuki
× Yamaguchi, Hiroyuki× Soda, Hiroshi× Nakamura, Yoichi× Takasu, Mineyo× Tomonaga, Nanae× Nakano, Hirofumi× Doi, Seiji× Nakatomi, Katsumi× Nagashima, Seiji× Takatani, Hiroshi× Fukuda, Minoru× Hayashi, Tomayoshi× Tsukamoto, Kazuhiro× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the efficacy of gefitinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the efficacy of gefitinib treatment. METHODS: We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status </=3, age </=80 years, and stage IIIB-IV disease. In addition, EGFR mutations were analyzed in 24 patients. RESULTS: Multivariate analysis showed that favorable progression-free survival (PFS) after gefitinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were significantly correlated with response to gefitinib and serum SP-D levels before treatment was significantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS. CONCLUSIONS: The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to gefitinib. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | The original publication is available at www.springerlink.com | |||||
書誌情報 |
Cancer chemotherapy and pharmacology 巻 67, 号 2, p. 331-338, 発行日 2011-02 |
|||||
出版者 | ||||||
出版者 | Springer Berlin | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 03445704 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14320843 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00598397 | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 20401612 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s00280-010-1325-x | |||||
権利 | ||||||
権利情報 | © Springer-Verlag 2010 | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
関係URI | ||||||
関連名称 | http://hdl.handle.net/10069/26688 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Cancer Chemotherapy and Pharmacology, 67(2), pp.331-338; 2011 |